Bicara Therapeutics (BCAX) Liabilities and Shareholders Equity (2023 - 2026)

Bicara Therapeutics has reported Liabilities and Shareholders Equity for 4 years, with the latest figure at $553.6 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 15.8% year-over-year to $553.6 million; the trailing twelve-month figure through Mar 2026 stood at $1.9 billion (up 23.19% YoY), and the FY2025 full-year result was $431.0 million, down 15.49% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $553.6 million, up from $431.0 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $553.6 million in Q1 2026, with the low at $234.0 million in Q4 2023.
• Historically, Liabilities and Shareholders Equity has averaged $451.1 million across 4 years, with a median of $465.8 million in 2025.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity surged 117.96% — and 2025, when it declined 18.98%.
• Bicara Therapeutics' Liabilities and Shareholders Equity stood at $234.0 million in 2023, then surged by 117.96% to $510.0 million in 2024, then dropped by 15.49% to $431.0 million in 2025, then grew by 28.45% to $553.6 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $553.6 million (Q1 2026), $431.0 million (Q4 2025), and $424.7 million (Q3 2025), per Business Quant data.